Human facilitating cells
View Patent ↗The present disclosure relates to human facilitating cells (hFC), and methods of isolating, characterizing, and using such hFCs.
1. A method of making a therapeutic human cellular composition for delivery to a recipient, comprising the steps of:
providing a donor source of human hematopoietic stem cells (HSCs);
depleting alpha beta TCR+T cells without significantly depleting HSCs or facilitating cells (FCs) from said donor source to produce a T cell-depleted donor source;
adjusting the number of alpha beta TCR+T cells in said T cell-depleted donor source to between about 2.0×10 6 and about 5.0×10 6 alpha beta TCR+T cells per kg recipient body weight,
thereby producing a therapeutic human cellular composition for delivery to a recipient.
2. The method of claim 1 , wherein said source of human HSCs is bone marrow, thymus, peripheral blood, fetal liver, or embryonic yolk sac.
3. The method of claim 1 , wherein said source of human HSCs is bone marrow.
4. The method of claim 1 , wherein the cells are depleted using one or more antibodies.
5. The method of claim 4 , wherein the one or more antibodies are conjugated to magnetic beads.
6. The method of claim 1 , wherein the number of alpha beta TCR+T cells are adjusted to between about 3.0×10 6 and about 4.2×10 6 alpha beta TCR+T cells/kg recipient body weight.
7. The method of claim 1 , wherein the therapeutic human cellular composition improves the engraftment ability of said human HSCs compared to human HSCs engrafted alone or in the absence of said therapeutic human cellular composition.